Background Multiple lines of evidence indicate that aspirin has an antineoplastic effect in the
large bowel. Randomized clinical trials have been conducted to evaluate the effectiveness …

Colorectal cancer is a major cause of morbidity and mortality accounting for an estimated
550,000 deaths annually worldwide. Colonic neoplasia develops in a stepwise fashion …

Background Preclinical studies indicate that the enzyme cyclooxygenase 2 plays an
important role in ultraviolet-induced skin cancers. We evaluated the efficacy and safety of …

Background: Multiple studies have indicated that specific COX-2 inhibitors may prevent
CRC. However, the long-term use of COX-2 inhibitors is not toxicity-free and may be limited …

The long-term (mean of 16.4±4.2 months) efficacy and safety of rofecoxib (a specific COX-2
inhibitor) in maintaining the colon free of polyps in familial polyposis patients was assessed …

Background Low-dose aspirin reduces the incidence of colorectal cancer and recurrence of
adenomas. Cyclooxygenase-2 (COX-2), one of its main target enzymes, is reportedly over …

The potential for cyclo-oxygenase inhibition in cancer prevention and treatment is founded
on epidemiology (reduction of colorectal cancer in aspirin users), animal experiments and …

Purpose: The aim of this study was to examine the effect of a specific cyclooxygenase-2
inhibitor, rofecoxib, on rectal polyps in familial adenomatous polyposis patients …

The identification and characterization of an inducible form of cyclooxygenase (COX-2) in
inflammatory cells in the early 1990s were the start of a race to the development of more …

Ample studies suggest that the cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2)
pathway plays a pivotal role in carcinogenesis and that COX-2 inhibition may help prevent …